Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant hormone therapy versus chemotherapy in hormone receptor-positive breast cancer
RBR-7wjw5z6Phase 3Not yet recruiting
- Sponsor
- IMIP
- Start
- Jan 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of anastrozole, goserelin, doxorubicin, cyclophosphamide and paclitaxel in breast cancer (2 arms), sponsored by IMIP. Primary endpoints: Clinical response success proportion and Pathological response success proportion. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
anastrozolegoserelindoxorubicincyclophosphamidepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on RBR-7wjw5z6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7wjw5z6.